focus -WSS

focus

author：leisure time 2025-09-05 15:35:35 - browse：81

empty test tubes in the hand. -- first opinion coverage from STAT — Adobe

The Food and Drug Administration on Friday announced its intention to start regulating tests developed in laboratories — closing the “Theranos loophole” that has allowed inaccurate tests to slip through the cracks.

Lawmakers came close last year to passing a bill that would have given the FDA this authority, but it was ultimately rejected by Republicans who sympathized with the labs in academic medical centers and hospitals that opposed the provision. FDA Commissioner Robert Califf said at the time that if the bill failed, the agency would take matters into its own hands.

The proposed rule fulfills that promise, adding lab diagnostics to the list of devices that fall under FDA enforcement — a move that patient groups and non-lab test makers support, and that laboratories are likely to dispute. When the FDA started regulating medical devices in 1976, lab-developed tests were simple and offered mostly to local patient populations. The agency generally allowed labs to use these tests without submitting proof of their efficacy.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Readout Newsletter: CAR

WSS

RaDonda Vaught links Vanderbilt hospital issues to patient death

Medicare coverage of Wegovy, once blocked, now looks possible

Elisabeth Bik tackles the widespread issue of research misconduct

Elisabeth Bik tackles the widespread issue of research misconduct

FDA advisers back CAR

HHS secretary Becerra pressed on Change HealthCare cyberattack

leisure time

focus

Wikipedia

Duchenne breakthrough therapy leaves behind pioneering families

5 ways to address the shortage of health care workers

Guidelines to prevent youth baseball injuries need more muscle

UCLA team creates talking throat patch for voice disorders

Hollywood unions extend contract negotiations for actors

As AI in medicine takes off, can 'human in the loop' prevent harm?

ChatGPT in medicine: STAT answers readers' burning questions

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Medicare proposal to cover medical devices draws a mixed reaction

5 ways to address the shortage of health care workers

leisure time

Medicare coverage of Wegovy, once blocked, now looks possible

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Readout Newsletter: GSK, Viking Therapeutics, mifepristone news

Boston's new lab space is opening empty

Redefining sustainability for the pharmaceutical industry

https://cbu01.alicdn.com/img/ibank/2016/006/421/3169124600_1941890905.220x220xz.jpg

leisure time

explore

entertainment

knowledge